|
Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Actinium Pharmaceuticals; Clovis Oncology; Endocyte; Progenics |
Honoraria - Progenics; Radiomedix |
Consulting or Advisory Role - Blue Earth Diagnostics |
|
|
Consulting or Advisory Role - ABX Advanced biochemical compounds; Blue Earth Diagnostics |
Research Funding - ABX Advanced biochemical compounds; Blue Earth Diagnostics; Siemens |
Patents, Royalties, Other Intellectual Property - patent application for rhPSMA |
Travel, Accommodations, Expenses - Bayer Schering Pharma |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Leadership - PFS Genomics |
Stock and Other Ownership Interests - Nutcracker Therapeutics, Inc.; PFS Genomics; SerImmune |
|
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Celgene; EMD Serono; Genzyme; Janssen Biotech; Medivation/Astellas |
Research Funding - Zenith Epigenetics |
Patents, Royalties, Other Intellectual Property - I helped develop a molecular signature to predict radiation resistance in breast cancer, and this signature was patented by the University of Michigan, my employer. It is in the process of being licensed to PFS Genomics, a company that I helped found. (Inst) |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - ImaginAb |
Consulting or Advisory Role - Astellas Pharma |
Speakers' Bureau - Genomic Health; ImaginAb; Janssen Oncology |
Patents, Royalties, Other Intellectual Property - patents surrounding discovery of PSCA and N-cadherin, owned by UCLA (Inst) |
|
|
Consulting or Advisory Role - Johnson & Johnson |
Speakers' Bureau - Bayer; Johnson & Johnson |
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst) |
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet. |
Travel, Accommodations, Expenses - Johnson & Johnson |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Fortis; Harpoon Therapeutics |
|
Consulting or Advisory Role - Beigene; Fortis; Janssen Oncology; Tolero Pharmaceuticals |
Research Funding - Janssen (Inst); Merck (Inst) |
Travel, Accommodations, Expenses - Janssen |
|
|
No Relationships to Disclose |
|
|
Honoraria - Intuitive Surgical |
Consulting or Advisory Role - Nutcracker Therapeutics, Inc. |
|
|
Stock and Other Ownership Interests - iTheranostics |
Honoraria - Advanced Accelerator Applications; Advanced Biochemical Compounds; Bayer; BTG; Curium Pharma; Endocyte; Sirtex Medical; SOFIE |
Consulting or Advisory Role - Advanced Accelerator Applications; Advanced Biochemical Compounds; Bayer; BTG; Curium Pharma; Endocyte; Sirtex Medical; SOFIE |
|
|
Leadership - SOFIE; Trethera |
Stock and Other Ownership Interests - SOFIE; Trethera |
Consulting or Advisory Role - Johannes Czernin is a founder, board member, and holds equity in Sofie Biosciences and Trethera Therapeutics. Intellectual property patented by the University of California is licensed to Sofie Biosciences and Trethera Therapeutics. Johannes Czernin serve |
|
|
Honoraria - GE Healthcare |
Consulting or Advisory Role - Curium Pharma; Ipsen |
Research Funding - Advanced Accelerator Applications (Inst); GE Healthcare; Philips Healthcare |
Travel, Accommodations, Expenses - GE Healthcare |